Related Experiment Video
Updated: Oct 2, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma
Nicole L Michmerhuizen1,2, Megan L Ludwig2,3, Andrew C Birkeland2
1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Background:
Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease with poor survival. Although epidermal growth factor receptor (EGFR)-targeting antibody cetuximab improves survival in some settings, responses are limited suggesting that alternative approaches are needed.
Methods:
We performed a high throughput drug screen to identify EGFR inhibitor-based synergistic combinations of clinically advanced inhibitors in models resistant to EGFR inhibitor monotherapies, and then performed downstream validation experiments on prioritized synergistic combinations.
Results:
From our screen, we re-discovered known synergistic EGFR inhibitor combinations with FGFR or IGF-1R inhibitors that were broadly effective and also discovered novel synergistic combinations with XIAP inhibitor and DNMT inhibitors that were effective in only a subset of models.
Conclusions:
Conceptually, our data identify novel synergistic combinations that warrant evaluation in future studies, and suggest that some combinations, although highly synergistic, will require parallel companion diagnostic development to be effectively advanced in patients.
Insights
New drug combinations show promise for treating head and neck squamous cell carcinoma (HNSCC). Researchers identified synergistic pairings of epidermal growth factor receptor (EGFR) inhibitors with other drugs to overcome treatment resistance.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) presents significant survival challenges.
- Current treatments targeting the epidermal growth factor receptor (EGFR) show limited efficacy in many patients, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify synergistic drug combinations involving EGFR inhibitors for HNSCC treatment.
- To validate these combinations in preclinical models, particularly those resistant to EGFR inhibitor monotherapy.
Main Methods:
- Conducted a high-throughput drug screen to discover synergistic combinations.
- Utilized clinically advanced inhibitors in EGFR-resistant models.
- Performed downstream validation experiments on prioritized combinations.
Main Results:
- Re-identified known synergistic combinations of EGFR inhibitors with FGFR or IGF-1R inhibitors, demonstrating broad efficacy.
- Discovered novel synergistic combinations with XIAP inhibitors and DNMT inhibitors, effective in specific subsets of models.
Conclusions:
- Identified novel synergistic drug combinations for HNSCC that warrant further clinical investigation.
- Highlighted the need for companion diagnostic development for certain highly synergistic combinations to guide patient selection for future trials.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12:03Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
Published on: July 25, 2011
